Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
530 participants
OBSERVATIONAL
2014-04-30
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Selective Aspiration Thrombectomy in STEMI
NCT03841487
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
NCT01347580
Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
NCT03991143
Impact of Ischemic Post-conditioning
NCT04068116
Exenatide for Myocardial Protection During Reperfusion Study
NCT01938235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing elective PCI
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective coronary intervention
* Minimum age of 18
Exclusion Criteria
* Age under 18
* Pregnancy
* Any additional invasive intervention with potential myocardial injury
* Non ACS conditions responsible for elevation of cardiac troponin, such as acute pulmonary artery embolism, myocarditis or tachycardia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
University Hospital Heidelberg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haitham Abu Sharar
Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haitham Abu Sharar, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Heidelberg
Evangelos Giannitsis, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Heidelberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology - University Hospital of Heidelberg
Heidelberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCI MI4a
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.